Weight Reduction Surgery and Ovarian Function

Obesity Clinical Trial

Official title:

The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00292773
• Other study ID #: STH14006
• Status: Completed
• Phase: N/A
• First received: February 15, 2006
• Last updated: July 19, 2011
• Start date: February 2006
• Est. completion date: February 2008

Study information

• Verified date: July 2011
• Source: Sheffield Teaching Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Observational

Clinical Trial Summary

This study will investigate the role of weight reduction surgery on the reproductive performance of obese women with ovulation problems. It is hypothesized that surgery offered when other methods of weight reduction have failed, may help restore ovulation.

Description:

We aim to recruit 30 patients suffering from chronic anovulation, with a body mass index of 35 or more, who failed to achieve weight reduction with other methods such as orlistat, metformin, diet and exercise.

Patients will be approached by one of the investigators in the infertility clinics and the assisted conception unit of the Royal Hallamshire hospital. Consent will be obtained by one of the designated investigators. The consent form has been designed in accordance with the guidelines of the central office for research and ethics committees (COREC). A patient information leaflet will be supplied and has been designed according to the COREC guidelines.

Patients will have a baseline history, clinical examination, hormonal profile (FSH/LH, fasting Insulin/glucose ratio, androgen profile, day 21 serum progesterone, serum leptin and ghrelin levels) ultrasound examination (ovarian volume and antral follicle count), including Doppler blood flow study (ovarian stromal velocity).

Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months. At each visit the following will be recorded:

1. Weight, menstrual diary.

2. Hormonal profile (FSH/LH, fasting Insulin/glucose ratio, androgen profile, day 21 serum progesterone, serum leptin and ghrelin levels).

3. Doppler of ovarian stroma (Pulsitility index, Peak velocity), ovarian volume and antral follicle count

4. Review of symptomatology especially androgenic symptoms.

End point:

Completion of six months follow up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Anovulation or irregular ovulation as determined by the following clinical or laboratory features:

• Clinical:

i. Irregular cycles (not 25-35 days) ii. Amenorrhoea (more than six months).

• Biochemical: Day 21 or midleuteal serum progesterone of less than 30mmol/l.

2. BMI of 35 or more.

3. Age between 18 and 45.

Exclusion Criteria:

1. Contraindication for bypass surgery:

i. Medically unfit ii. Psychologically unfit iii. Strong family history of gastric cancer

2. Insulin dependant diabetes or patients on oral hypoglycaemics. Insulin resistance and impaired glucose tolerance however, are not exclusion criteria.

3. Concomitant endocrine disorders including thyroid disease and Cushing syndrome.

4. Patients on steroid therapy.

5. Patients who have had one or both ovaries removed.

6. Biochemical evidence of ovarian failure i.e. FSH of 20 IU or more.

7. Patients who have had hysterectomy.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Anovulation
• Obesity
• Weight Loss

Intervention

Procedure:
• weight reduction minimal access surgery
Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.

Locations

Country	Name	City	State
United Kingdom	Jessop Wing, Royal Hallamshire Hospital	Sheffield

Sponsors (1)

Lead Sponsor	Collaborator
Sheffield Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom,